Apr 10, 2023 08:00AM Avadel Pharmaceuticals to Present at the 22nd Annual Needham Healthcare Conference

Mar 30, 2023 05:48AM Avadel Pharma (AVDL) Prices $125M Offering of ADSs and Series B Preferred Shares

Mar 29, 2023 09:24PM Avadel Pharmaceuticals Announces Pricing of Public Offering of ADSs and Series B Preferred Shares

Mar 29, 2023 04:13PM Avadel Pharma (AVDL) Announces Proposed Share Offering

Mar 29, 2023 04:13PM Avadel Pharmaceuticals Announces Proposed Underwritten Public Offering of ADSs and Series B Preferred Shares

Jul 1, 2022 05:54AM Needham & Company Reiterates Buy Rating, $6 Price Target on Avadel Pharmaceuticals (AVDL), Sees $300M Opportunity for FT218 in Narcolepsy

Apr 12, 2022 05:57AM Needham & Company Reiterates Avadel Pharmaceuticals (AVDL) at Buy with $15 PT, "Incrementally More Positive on AVDL" Following Recent Management Chat

Mar 22, 2022 08:00AM Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

Feb 22, 2022 05:48AM Needham & Company Reiterates Buy Rating on Avadel Pharmaceuticals (AVDL), Believes FDA Decision on FT218 Could be Coming Soon

Jan 11, 2022 06:54AM Avadel Pharma's (AVDL) FT218 is Approvable, But Timeline Remains Unclear - Needham & Company

Nov 8, 2021 01:27PM Avadel Pharmaceuticals (AVDL): FDA Reviews of FT-218 Continues to Make Progress - Needham & Company

Oct 18, 2021 07:17AM Avadel Pharmaceuticals (AVDL) PT Lowered to $16 at Needham & Company But Remaining Optimistic of an Approval

Sep 22, 2021 04:14PM Needham & Company Starts Avadel Pharmaceuticals (AVDL) at Buy